298 related articles for article (PubMed ID: 33750817)
21. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
[No Abstract] [Full Text] [Related]
22. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
23. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
Gardellini A; Guidotti F; Feltri M; Zancanella M; Maino E; Ambrosiani L; Turrini M
Blood Cells Mol Dis; 2021 Dec; 92():102620. PubMed ID: 34715450
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
[TBL] [Abstract][Full Text] [Related]
25. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
26. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Burness CB; Keating GM; Garnock-Jones KP
Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
[TBL] [Abstract][Full Text] [Related]
27. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
[TBL] [Abstract][Full Text] [Related]
28. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP.
Liu XG; Liu S; Feng Q; Liu XN; Li GS; Sheng Z; Chen P; Liu Y; Wei Y; Dong XY; Qin P; Gao C; Ma C; Zhang L; Hou M; Peng J
Blood; 2016 Aug; 128(6):852-61. PubMed ID: 27281793
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey.
Koca Yozgat A; Leblebisatan G; Akbayram S; Çınar Özel S; Karakaş Z; Erduran E; Yılmaz Ş; Koçak Ü; Ünal Ş; Özdemir GN; Albayrak M; Zengin E; Oymak Y; Bör Ö; Çakmaklı HF; Söker M; Gürlek Gökçebay D; Tokgöz H; Malbora B; Karaman S; Celkan T; Şaşmaz İ; Yaralı N; Ören H; Ünüvar A; Özbek NY
Turk J Haematol; 2020 Aug; 37(3):139-144. PubMed ID: 32181630
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis.
Patwardhan P; Landsteiner A; Lal LS; Geevarghese L; Le L; Nandal S; Cuker A
Ann Hematol; 2022 Jan; 101(1):11-19. PubMed ID: 34505942
[TBL] [Abstract][Full Text] [Related]
33. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan].
Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T
Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682
[TBL] [Abstract][Full Text] [Related]
34. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
35. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Chen M; Fang JP; Zhou CX; Li XY; Lin SF; Xu LH
Hematology; 2021 Dec; 26(1):31-36. PubMed ID: 33357172
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
[TBL] [Abstract][Full Text] [Related]
39. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
40. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
